A prospective, multicentre, open-label, randomized, phase II study of Pembrolizumab in combination with neoadjuvante (F)EC-Paclitaxel regimen in HER2-negative inflammatory breast cancer.
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Paclitaxel
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 06 May 2019 Status changed from not yet recruiting to recruiting.
- 03 May 2018 Planned End Date changed from 8 Sep 2024 to 30 Apr 2025.
- 14 Sep 2017 New trial record